exploratory study of optimizing ustekinumab dosing interval in ulcerative colitis

exploratory study of optimizing ustekinumab dosing interval in ulcerative colitis - exploratory study of optimizing ustekinumab dosing interval in ulcerative colitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046650

Enrollment

Registered

2022-01-18

Start date

2020-10-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Endoscopy was performed 28 to 32 weeks after the administration of ustekinumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients aged 20 years or older at the time of obtaining the consent form. 2. Patients with ulcerative colitis who received ustekinumab. 3. Ulcers that have already started treatment with ustekinumab but have not undergone endoscopy after treatment within 24 weeks

Exclusion criteria

Exclusion criteria: 1.Patients judged by the principal investigator to be inappropriate as subjects 2.Patients without discernment 3.Patients who cannot obtain written consent

Design outcomes

Primary

Measure	Time frame
endoscopic therapeutic effects and clinical findings after UST administration at week 28 to 32.	—

Secondary

Measure	Time frame
Lichtiger index, white blood cells, platelets, albumin, C-reactive protein, erythrocyte sedimentation rate	—

Countries

Japan

Contacts

Public ContactYUKA FUKUO

JUNTENDO UNIVERSITY NERIMA HOSPITAL Gastroenterology

yfukuo@juntendo.ac.jp03-5923-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026